Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors

Abstract

✓ Oral 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), a lipid-soluble non-ionized chemotherapeutic agent, was used in the treatment of 26 patients with malignant brain tumor, primarily glioblastoma. Most patients had first received conventional surgery, and about one half had received x-ray therapy. Over 1½ years, 113 courses of CCNU (130–150 mg/m2) were given and analyzed for clinical results and agent toxicity. A new central nervous system (CNS) disease staging system was used to measure patient impairment and therapeutic response. Thirty-seven per cent of all symptomatic patients had significant remission of clinical disease, lasting a median of 5 months. Data are presented implying that the treatment of asymptomatic patients may also be of considerable value. The most significant toxicity was delayed reversible thrombocytopenia, which was less severe than that seen with nitrosourea BCNU. Despite the cumulative toxicity observed with all three bone-marrow elements, serious complications were rare. Our initial experience indicates that CCNU is an effective agent for the treatment of malignant brain tumor and that the CNS disease staging system is useful in obtaining quantitative results.